How is refractory hypoglycemia treated in patients with insulinoma?

Updated: May 31, 2020
  • Author: Zonera Ashraf Ali, MBBS; Chief Editor: Neetu Radhakrishnan, MD  more...
  • Print

Off-label use of other agents has been described in case reports. [47, 48] Pasireotide, a novel multireceptor somatostatin analogue, has been used for treatment of refractory hypoglycemia in malignant insulinoma. The multitargeted receptor tyrosine kinase inhibitor sunitinib has been used; sunitinib has antiangiogenic and antitumor activity, but does not appear to have a direct action on glycemic control, and indeed may worsen hypoglycemia. [48]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!